Clinical Trials Browser

Phase 2 × RFT5-SMPT-dgA immunotoxin × Clear all

NCT01378871 2023-06-09

A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma

Phase 2 Terminated

1 enrolled 8 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT00667017 2018-12-14

RFT5-dgA Immunotoxin in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma

Phase 2 Terminated

1 enrolled 1 chart

DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00025662 2016-10-28

Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS

Phase 2 Completed

23 enrolled 11 charts

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Graft vs Host Disease, Hodgkin Disease, Leukemia, Leukemia, Lymphoid, Leukemia, Myeloid, Lymphoma, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma